https://www.ashi-hla.org/forums/posts.aspx?topic=1371451 Sat, 6 Jun 2026 11:57:11 GMT Thu, 13 Jul 2017 16:55:45 GMT Copyright © 2017 American Society for Histocompatibility and Immunogenetics https://www.ashi-hla.org/forums/posts.aspx?topic=1371451 https://www.ashi-hla.org/forums/posts.aspx?topic=1371451 We all know that the Bw4 or Bw6 pattern on SAB is something to be very careful about. However, I could not find hard evidence on the clinical significance of very low level anti-Bw4 or anti-Bw6.
If you see a distinct but very low "hill" of Bw4 or Bw6 (MFI below 1000) in a Bw6/6 or Bw4/4 candidate, and a surrogate crossmatch is negative, would you list Bw4 or Bw6 as avoids at UNOS? (which will exclude 60-90% of the donors)
If no and the patient receives a graft with the corresponding epitope, do you routinely recommend prophylactic rituximab to prevent AMR?
Thank you so much for sharing your thoughts!
Sincerely,
Chang Liu, MD PhD
HLA laboratory, Wash U/Barnes-Jewish Hospital]]> Thu, 13 Jul 2017 17:55:45 GMT